Related Experiment Video
Updated: Jun 28, 2026
10:31
An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment
Published on: April 20, 2018
Obesity and the metabolic syndrome in developing countries
1Department of Diabetes and Metabolic Diseases, Fortis Flt. Lt. Rajan Dhall Hospital, Vasant Kunj, New Delhi 110070, India. anoopmisra@metabolicresearchindia.com
The Journal of Clinical Endocrinology and Metabolism
|December 4, 2008
Summary
Obesity and metabolic syndrome are rising in developing nations, increasing risks of type 2 diabetes and heart disease. Urgent interventions focusing on nutrition and physical activity, especially for children, are needed.
Area of Science:
- Public Health
- Epidemiology
- Nutrition Science
Background:
- The prevalence of obesity and metabolic syndrome is escalating globally, particularly in developing countries.
- This rise contributes to increased rates of type 2 diabetes mellitus (T2DM) and cardiovascular disease.
Purpose of the Study:
- To review the current literature on obesity and metabolic syndrome in developing countries.
- To identify causes, consequences, and potential intervention strategies for these conditions.
Main Methods:
- A comprehensive literature search was conducted using keywords related to obesity, metabolic syndrome, and developing countries.
- Databases searched included PubMed (1966-2008) and resources from the World Health Organization and Food and Agricultural Organization.
Main Results:
- Obesity and metabolic syndrome are increasing in developing countries due to urbanization, dietary shifts, and decreased physical activity.
- Perinatal undernutrition and childhood obesity may contribute to adult metabolic syndrome and T2DM.
- The economic burden of obesity-related diseases is substantial for developing nations with limited health budgets.
Conclusions:
- Large-scale community interventions promoting physical activity and healthy eating, especially for children, are crucial.
- International health organizations and governments must prioritize primary and primordial prevention programs for obesity and metabolic syndrome.
Related Concept Videos
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...